What investment strategy does Truffle Capital focus on?

Truffle Capital focuses on VC, Growth strategies in the private equity space.

How many portfolio companies does Truffle Capital have?

Truffle Capital has 8 active portfolio companies and 7 completed exits and 3 funds tracked on GP Intel.

Where is Truffle Capital headquartered?

Truffle Capital is headquartered in PARIS, France.

What is Truffle Capital's assets under management?

Truffle Capital manages approximately €1.2B in assets under management.

When was Truffle Capital founded?

Truffle Capital was founded in 2000.

What sectors does Truffle Capital invest in?

Truffle Capital invests across Healthcare, Financials, Software.

Home/GPs/Truffle Capital

Truffle Capital

PARIS, France·Founded 2000·

Venture Capital Growth Equity

·truffle.com

Truffle Capital is an independent European venture capital firm founded in 2001, focused on building and financing innovative companies in the Life Sciences (MedTech and Biotech) and IT sectors (FinTech and InsurTech). It manages €500…Read full bio

AUM

€1.2B

Funds

Portfolio

SectorsHealthcareFinancialsSoftware

Key facts

HQPARIS, France

Founded2000

Websitetruffle.com

Recent exits

Software · 2024

Software · 2022

TMT · 2021

Software · 2021

Coverage notes

3 funds tracked, 15 portfolio companies (8 active · 7 realized). Verified weekly from public filings and deal announcements.

About Truffle Capital

Truffle Capital is an independent European venture capital firm with €1.2 billion of assets under management as of December 2024, founded in 2001 and headquartered in Paris. The firm focuses on building and financing innovative companies in Life Sciences (MedTech and Biotech) and IT sectors (FinTech and InsurTech), with the platform supporting European early-stage and growth-stage innovation across two core verticals over a multi-decade track record.

Investment thesis

Truffle deploys venture capital across two complementary verticals: Life Sciences (MedTech medical devices, Biotech drug development) and IT (FinTech, InsurTech, enterprise software). Investment stages span early-stage seed and Series A through growth equity commitments, with equity tickets typically ranging from €2 million to €30 million per transaction depending on stage and sub-vertical. The dual vertical focus enables deep scientific and technology expertise across both healthcare innovation and digital finance innovation.

Recent activity

Recent realised exits include RETENCY (software, 2024) and PHARNEXT (software, 2022), reflecting selective distribution activity across the technology portfolio. The platform tracks 3 funds, 8 active portfolio companies and 7 realised exits across the dual Life Sciences and IT venture programme. Detailed buyer names and multiple data available on Pro at €49/month.